HIV Policy

Halliwell et al., 2024, led by Pamuela Halliwell, MA, LMFT at The San Diego LGBT Community Center and Laramie Smith, PhD at UCSD, documents the devastating violence that disproportionately impacts Black transgender women. Findings reveal that Black transgender women accounted for 78% of all transgender women murdered in the U.S., with gun violence as the leading cause and Southern and Midwestern regions showing the highest rates of violence, linked to structural racism and anti-transgender policies.

Read More
HIV Policy
Fatal Violence Against Black Transgender Women in the United States

November 18, 2024

Kelly et al., 2024, led by Dr. Nicole Kelly from UC San Diego with co-authors at the University of North Carolina, examines the profound impact of state and local LGBTQ+ policies on HIV prevention among young SGM people, especially Black youth. The study highlights that PrEP (pre-exposure prophylaxis) use among young people significantly increases in regions with protective LGBTQ+ legislation, while discriminatory policies hinder access to life-saving prevention tools

Read More
HIV Policy
The Relationship Between Anti-LGBTQ+ Legislation and HIV Prevention Among Sexual and Gender Minoritized Youth

November 18, 2024

For 340B-covered entities, core to the challenge of navigating a changing and uncertain policy landscape is the complexity of how multiple variables interact differently with each covered health care entity based on its unique makeup of services, funding, patient population, and payer mix. This toolkit aims to assist 340B covered entities in understanding their current areas of funding stability and where they are vulnerable, and to plan for the future.

Read More
HIV Policy
Navigating changes to the 340B drug pricing program: a toolkit for HIV-related healthcare entities in California

October 4, 2024

In light of proposed and actual changes in Federal and State policy that have the potential to affect the 340B program, we conducted a rapid response study, exploring the impact to facilities that serve people living with or at risk for HIV. As a companion to the Navigating 340B Toolkit, this Explainer takes a closer look at the answers to these three questions: 1. How does 340B work? 2. What is the relationship between 340B and HIV services? 3. What are the current factors impacting 340B revenue for HIV clinical and service organizations?

Read More
HIV Policy
Navigating 340B amidst policy changes: an explainer

October 4, 2024

A new paper published in JAIDS finds that pharmacists could play a key role in providing long-acting injectable pre-exposure prophylaxis (PrEP) for HIV prevention. In a mixed methods analysis of survey and interview data, CHPRC researchers found that many pharmacists would be willing to administer injectable PrEP if provided with training, compensation, and a private room. However, pharmacists may require additional resources and policy support to make widespread implementation feasible.

Read More
HIV Policy
A mixed methods evaluation of pharmacists’ readiness to provide long-acting injectable HIV pre-exposure prophylaxis in California

September 25, 2024